The global Oligonucleotide CDMO Market, valued at US$2.33 billion in 2023, is forecasted to grow at a robust CAGR of 21.8%, ...

Oligonucleotide therapeutics are becoming increasingly popular, with scientists developing treatments for rare diseases, cancer, and respiratory disorders. To ensure their quality, researchers must ...

Cure Rare Disease has been awarded a $5.69 million grant from the California Institute for Regenerative Medicine (CIRM) to advance the development of an antisense oligonucleotide therapy for ...

Oligonucleotide probes are short stretches of single-stranded DNA or RNA used to detect the presence of complementary nucleic acid sequences (target sequences) by hybridization. Oligonucleotide ...

Our expert speakers will also discuss how to apply the Oligo Analysis Accelerator for OpenLabs CDS to your oligonucleotide therapeutic testing, helping you to optimize synthesis and purification.

With the rapid increase in the development of oligonucleotide therapeutics and gene therapies, workflows for the identification, characterization and quantification of full-length products, their ...

REDWOOD CITY, Calif. - Codexis , Inc. (NASDAQ: NASDAQ:CDXS), a prominent player in enzymatic solutions for pharmaceutical manufacturing whose stock has surged over 50% in the past year, announced ...

CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting antisense oligonucleotide (ASO) therapies to upregulate gene ...

(NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the appointment of Arthur Levin, PhD, to the Company’s Strategic ...